VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Borna disease virus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
  2. Vaccine Related Pathogen Genes
    1. p10 (Protective antigen)
  3. Vaccine Information
    1. rORFV-p40(Borna disease virus)
  4. References
I. General Information
1. NCBI Taxonomy ID:
12455
1. p10
  • Gene Name : p10
  • Sequence Strain (Species/Organism) : Borna disease virus
  • NCBI Protein GI : AAX09334
  • Other Database IDs : CDD:115187
  • Taxonomy ID : 1714621
  • Protein Name : p10
  • Protein pI : 10.74
  • Protein Weight : 7848.852
  • Protein Length : 126
  • Protein Note : Borna disease virus P10 protein; pfam06515
  • Protein Sequence : Show Sequence
    >AAX09334.1 p10, partial [Borna disease virus 1]
    VRANGTRPHQSGKIPGGRRRSPDTTTGTIGVTKTTEGPKECIDPTSRPAPEGPQEEPLHDLRPRPANRKG
    AAVE
    
    
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : (Hashimoto et al., 2003)
III. Vaccine Information
1. rORFV-p40(Borna disease virus)
a. Vaccine Ontology ID:
VO_0004769
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
The highly attenuated Orf virus strain D1701 was used to generate a recombinant virus (D1701-VrVp40) expressing nucleoprotein p40 of Borna disease virus (Henkel et al., 2005).
f. Immunization Route
Intramuscular injection (i.m.)
g. Rat Response
  • Vaccination Protocol: The rats were immunized at an age of 4 to 5 weeks in 2-week intervals by intramuscular application of D1701-VrVp40 (Henkel et al., 2005).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: 2 weeks after the last immunization 5 ×103 to 10 ×103 FFU of BDV were used for intracerebral challenge infection (Henkel et al., 2005).
  • Efficacy: Rats immunized with D1701-VrVp40 exhibited protection against Borna Disease, and virus clearance from the infected brain was demonstrated in immunized animals. Even 4 and 8 months after the last immunization, all immunized animals were still protected against the disease (Henkel et al., 2005).
IV. References
1. Hashimoto et al., 2003: Hashimoto Y, Chen HS, Cunningham C, Malik TH, Lai PK. Two major histocompatibility complex class I-restricted epitopes of the Borna disease virus p10 protein identified by cytotoxic T lymphocytes induced by DNA-based immunization. Journal of virology. 2003; 77(10); 6076-6081. [PubMed: 12719601].
2. Henkel et al., 2005: Henkel M, Planz O, Fischer T, Stitz L, Rziha HJ. Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. Journal of virology. 2005; 79(1); 314-325. [PubMed: 15596826].